Open AccessThe Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Author(s) -
Kimberly R. Jordan,
Matthew J. Sikora,
Jill E. Slansky,
Angela Minic,
Jennifer K. Richer,
Marisa R. Moroney,
Junxiao Hu,
Rebecca J. Wolsky,
Zachary L. Watson,
Tomomi M. Yamamoto,
James C. Costello,
Aaron Clauset,
Kian Behbakht,
T. Rajendra Kumar,
Benjamin G. Bitler
Publication year - 2020
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-20-1762
Subject(s) - ovarian cancer , tumor microenvironment , medicine , cancer research , cytokine , cancer , serous fluid , gene signature , oncology , biology , immunology , gene expression , gene , biochemistry
Ovarian cancer has one of the highest deaths to incidence ratios across all cancers. Initial chemotherapy is effective, but most patients develop chemoresistant disease. Mechanisms driving clinical chemo-response or -resistance are not well-understood. However, achieving optimal surgical cytoreduction improves survival, and cytoreduction is improved by neoadjuvant chemotherapy (NACT). NACT offers a window to profile pre- versus post-NACT tumors, which we used to identify chemotherapy-induced changes to the tumor microenvironment.